PIP-based tumor-targeting platform

The PIP-based tumor-targeting platform is a synthetic, ultra-stable peptide technology designed to selectively target and penetrate solid tumors by binding multiple tumor-associated integrins in their active conformations. This multi-targeting approach enables broad applicability across various solid tumor types while minimizing exposure to healthy tissues. The platform is modality-agnostic with tunable pharmacokinetics, allowing it to be conjugated with diverse therapeutic payloads including cytotoxic drugs and immunotherapies. Developed initially in the laboratory of Jennifer Cochran at Stanford University, the PIP molecule facilitates targeted delivery by exploiting rapid internalization of integrins on cancer cells, enabling intracellular release of attached drugs or surface-bound therapies. It has demonstrated superior tumor penetration and accumulation compared to antibody-drug conjugates in preclinical models.

Other names

PIP agentpolyspecific integrin-binding peptide (PIP)